During Wednesday’s trade, Shares of MannKind Corporation (NASDAQ:MNKD), lost – 10.42 % to $0.673.
MannKind Corporation (NASDAQ:MNKD) (MNKD) declared the termination of its license and partnership agreement with sanofi-aventis U.S. LLC for the development and commercialization of Afrezza® (insulin human) Inhalation Powder. The parties will promptly commence transition negotiations in order to effect a smooth and orderly transition in the development and commercialization of Afrezza from Sanofi to MannKind over the next 90 – 180 days. In any event, termination of the license agreement in its entirety will be effective no later than six months from the effective date of Sanofi’s notice of termination, or July 4, 2016.
MannKind is reviewing its planned options for Afrezza as a result of the termination of the partnership with Sanofi.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes.
Shares of Pfizer Inc. (NYSE:PFE), declined -1.26% to $31.77, during its current trading session.
Pfizer Inc. invites investors and the general public to listen to a webcast of a joint negotiation with Pfizer and Allergan administration at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 10:30 a.m. Pacific Standard Time.
Pfizer speakers will be Ian Read, Chairman and CEO, Mikael Dolsten, President, Worldwide Research and Development, and Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business. Allergan speakers will be Brent Saunders, CEO and President, David Nicholson, Executive Vice President and President, Global Brands Research & Development, and William Meury, Executive Vice President and President, Branded Pharma.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Finally, Shares of Merck & Co., Inc. (NYSE:MRK), lost -0.66%, and is now trading at $52.80.
Merck (MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Wednesday, Feb. 3. During the call, company executives will provide an overview of Merck’s performance for the quarter and full year.
Investors, journalists and the general public may access a live audio webcast of the call on Merck’s website at http://www.merck.com/investors/events-and-presentations/home.html. A replay of the webcast will be available at about 11:00 a.m. EST on Feb. 3 and will remain on the website for 12 months. The sales and earnings news release and supplemental financial disclosures also will be available in the Newsroom and Investor sections of the company’s website at www.merck.com.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.